Infectious disease testing continues to be one of the most dynamic and high-impact areas of laboratory medicine. Providers are demanding faster turnaround times, broader pathogen coverage, and clinically actionable results, while laboratories face rising costs and increasing scrutiny from payers.
Multiplex infectious disease testing, particularly Single Tube Assay (STA) molecular testing, provides laboratories with a means to meet these demands without overextending operational resources. By combining efficiency, flexibility, and clinical rigor, multiplex STA testing has become an increasingly attractive option for laboratories looking to expand or optimize their molecular diagnostics menu.
What Is Multiplex Single Tube Assay (STA) Testing?
Multiplex Single Tube Assay (STA) testing is a real-time PCR-based approach that enables simultaneous detection of multiple infectious disease targets within a single reaction well. Rather than running multiple assays across several wells (or wasting unused portions of full plates) STA testing consolidates testing into a streamlined workflow.
Key assay characteristics include:
- Detection of 1–5 pathogen targets per tube
- Built-in internal control (RNase P) included in every reaction
- Low reaction volume (10 µL) for reduced reagent use
- Approximately 200 reactions per tube, including controls
For laboratories, this design translates to less waste, lower per-test reagent costs, and improved flexibility when managing variable testing volumes.
Why Laboratories Are Adopting Multiplex STA Infectious Disease Testing
- Reduced Waste and More Predictable Costs
Traditional multiplex PCR panels often require full-plate utilization to remain cost-effective. STA testing eliminates this constraint by allowing laboratories to run only what they need, when they need it. Using a single well per sample significantly reduces:
- Master mix consumption
- Plate waste
- Unused reagents tied up in partially run plates
This efficiency is particularly valuable for laboratories with fluctuating daily volumes or those launching new molecular service lines.
- Broad Infectious Disease Coverage Without Overcomplication
Multiplex STA testing supports many of the highest-demand infectious disease categories, including:
- Urinary Tract Infections (UTI) with Antimicrobial Resistance (ABR)
- Wound and skin infections
- Women’s Health testing
- Sexually Transmitted Infections (STI)
- Nail and fungal infections
Laboratories can order individual assays or bundled panels, allowing menu expansion without committing to rigid, one-size-fits-all panel designs. This flexibility helps labs align testing offerings with local provider demand and patient populations.
The Importance of Extraction in Infectious Disease Molecular Testing
While extraction-free molecular workflows are often marketed as cost-saving solutions, internal data highlighted in your materials reinforces an important reality: nucleic acid extraction remains critical for reliable infectious disease testing.
Studies cited show that extraction-free methods may result in:
- Increased limits of detection (LOD)
- Less than 95% agreement in patient correlation studies
- Greater variability across sample types
By continuing to rely on automated extraction platforms, multiplex STA testing supports consistent sensitivity, and clinical confidence, key factors for both provider adoption and payer compliance.
Customization Options Without Excessive Complexity
Although the STA platform prioritizes standardized, validated panels, customization is available when testing volume justifies it. Options include:
- Adding or modifying targets
- Dye reconfiguration
- Custom assay development with defined timelines and costs
Importantly, customization is approached strategically to avoid unnecessary validation burden, helping laboratories maintain operational discipline while still differentiating their test menus when appropriate.
Validation Transparency: A Critical Advantage
One of the biggest barriers to expanding molecular testing is uncertainty around validation requirements. The STA offering clearly outlines:
- Expected validation costs
- Required specimen types
- Accuracy, interference, exclusivity, and correlation studies
This transparency allows laboratory leaders to budget accurately, plan timelines, and avoid surprises, making multiplex STA testing a scalable and manageable investment.
The Strategic Case for Multiplex STA Testing
Laboratories are adding multiplex STA infectious disease testing to:
- Expand high-demand molecular test menus
- Improve turnaround times for clinicians
- Reduce reagent waste and operational inefficiencies
- Support antimicrobial stewardship initiatives
- Strengthen molecular testing revenue streams
When implemented thoughtfully, multiplex STA testing becomes not just a clinical upgrade, but a strategic growth opportunity.
Instrumentation Compatibility and Workflow Integration
Multiplex STA assays are compatible with most common PCR and extraction instruments. Supported instruments include QuantStudio 5, 6, 7, and 12 Flex systems.
For laboratories with existing molecular infrastructure, STA testing offers a way to maximize instrument utilization without significant capital reinvestment or workflow disruption.
How Lighthouse Lab Services Helps Laboratories Succeed
Successfully implementing multiplex infectious disease testing requires more than just assays. From instrumentation planning and validation to workflow optimization and reimbursement strategy, execution matters.
Lighthouse Lab Services partners with laboratories to:
- Design scalable molecular testing workflows
- Support validation and compliance requirements
- Optimize lab operations and revenue cycle performance
- Ensure long-term sustainability of molecular service lines
Multiplex Single Tube Assay testing represents a practical evolution in molecular diagnostics; one that aligns clinical performance with operational and financial realities. For laboratories seeking to expand infectious disease testing without unnecessary complexity or waste, STA-based multiplex panels offer a clear path forward.
Contact us today for a complementary consultation to learn more.
